Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Molecular Endocrinology (Baltimore, Md.)|October 1, 1992
Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivityA M Brunner, M N Lioubin, H Marquardt, et al.Investigative Radiology|February 17, 2006
In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 TeslaShelton D Caruthers, Anne M Neubauer, Frank D Hockett, et al.Nanomedicine (London, England)|August 25, 2007
Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticlesGregory M Lanza, Patrick M Winter, Shelton D Caruthers, et al.Nature Medicine|June 9, 2015
Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonizationDi Fan, Laura A Coughlin, Megan M Neubauer, et al.Circulation. Cardiovascular Interventions|February 2, 2010
Clinical feasibility of a fully automated 3D reconstruction of rotational coronary X-ray angiogramsAnne M Neubauer, Joel A Garcia, John C Messenger, et al.Diabetes, Obesity & Metabolism|August 6, 2013
Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patientsJ K Mader, K M Neubauer, L Schaupp, et al.Magnetic Resonance in Medicine|October 29, 2008
Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imagingAnne M Neubauer, Jacob Myerson, Shelton D Caruthers, et al.Science (New York, N.Y.)|May 14, 2005
Titan's magnetic field signature during the first Cassini encounterHeiko Backes, Fritz M Neubauer, Michele K Dougherty, et al.Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|March 17, 2007
Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agentsAnne M Neubauer, Shelton D Caruthers, Franklin D Hockett, et al.Annals of Hematology|December 24, 1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyM A Fridrik, R Greil, H Hausmaninger, et al.Pageof 14